ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0398

Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data

Mary Eckert1, Eveline Wu2, Melissa Oliver3, Joshua Scheck4, Sivia Lapidus5, Ummusen Kaya Akca6, Shima Yasin7, Aleksander Lenert8, Sara Stern9, Antonella insalaco10, Manuela Pardeo10, Gabriele Simonini11, Edoardo Marrani12, Xing Wang13, Bin Huang14, Leonard Kovalick15, Natalie Rosenwasser16, Erin Balay-Dustrude17, Gabriel Casselman16, Liau Adriel18, Ava Klein18, Yurong Shao4, Claire Yang4, Molly Briggs4, Emily Deng4, Iris Hamilton4, Ethan Mueller16, Elise Machrone4, Paige Trunnel4, Doaa Mosa19, Lori Tucker20, Hermann Girschick21, Ronald Laxer22, Georgina Tiller23, Jonathan Akikusa24, Christian Hedrich25, Karen Onel26, Fatma Dedeoglu27, Marinka Twilt28, Seza Ozen29, Polly Ferguson30, Laura Schanberg31, Bryce Reeve32 and Yongdong (Dan) Zhao33, 1Seattle Children's, Mercer Island, WA, 2University of North Carolina School of Medicine, Chapel Hill, NC, 3Indiana University, Indianapolis, IN, 4Seattle Children's Hospital, Seattle, 5Hackensack University Medical Center, Montclair, NJ, 6Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 7University of Iowa Carver College of Medicine, Abu Dhabi, United Arab Emirates, 8University of Iowa, Iowa City, IA, 9University of Utah, Salt Lake City, UT, 10IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 11Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 12University of Florence, Firenze, Florence, Italy, 13Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, 14Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, 15UNC Health Care, Durham, NC, 16Seattle Children's Hospital, Seattle, WA, 17University of Washington, Seattle, WA, 18Seattle Children’s Research Institute, University of Washington, Seattle, 19Mansoura University Hospital, Mansoura City, Egypt, 20BC Children's Hospital, Vancouver, BC, Canada, 21Vivantes Clinic Friedrichshain, Wuerzburg, Germany, 22SickKids, Toronto, ON, Canada, 23University of British Columbia - Vancouver, Vancouver, BC, Canada, 24Royal Children's Hospital, Parkville, Victoria, Australia, 25University of Liverpool, Liverpool, United Kingdom, 26HSS, New York, NY, 27Boston Children's Hospital, Boston, MA, 28Alberta Children's Hospital, Calgary, AB, Canada, 29Department of Pediatrics, Hacettepe University, Ankara, Turkey, 30University of Iowa Carver College of Medicine, Iowa City, IA, 31Duke University Medical Center, DURHAM, NC, 32Duke University School of Medicine, Durham, 33University of Washington, Redmond, WA

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Disease Activity, Outcome measures, Patient reported outcomes, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported outcome measures. The PROMIS pediatric measures, validated in other pediatric rheumatic diseases, were administered to children with CNO enrolled in the prospective multisite CHronic nonbacterial Osteomyelitis International Registry (CHOIR). Our objective was to assess the convergent and responsive validity of the PROMIS instruments in patients with CNO.

Methods: Children or young adults with CNO were consented and enrolled into CHOIR. Self-reported PROMIS questionnaires of fatigue, pain interference (PI), pain behavior (PB), mobility, upper extremity (UE), physical activity (PA) and strength impact (SI) were administered to patients 8 years and older in English at each clinical visit. Demographic, clinical, and imaging data were prospectively collected. The T score was calculated. External validation surveys were administered to assess patients’ perception of difficulty of use of limb/back/jaw, fatigue, sadness and worry on a 0-10 scale, disease status (inactive, mild, moderate, severe), and status change (unchanged, worsened, improved). Improvement of clinical disease activity score (CDAS) of 2.5 was defined as meaningful change. Descriptive statistics were used for demographic and clinical characteristics. Log-transformed linear mixed effect models with random participant intercepts were performed to assess PROMIS score changes after treatment. Wilcoxon signed-rank test with continuity correction was performed to determine the change of the PROMIS scores among the improved, worsened, and unchanged groups. Spearman rank correlation test was performed to determine the relationship between the PROMIS scores and reported disease status by patient/families.

Results: More than 1,000 clinical visits from 184 patients were associated with self-reported PROMIS questionnaire entries in English. Demographic characteristics are shown in Table 1. All  PROMIS scores correlated significantly (p< 0.01) with  patient reported variables and physician global assessment (PGA)  (Table 2). The correlation with functional difficulty and PGA was good (0.4-0.6) for Mobility, PB, and PI. All PROMIS scores, except  physical activity,  correlated significantly (p< 0.05) with patient reported disease status (Figure 1). The changes of PROMIS scores over time for Mobility, PB, PA, and PI compared to the self-reported status change (unchanged, improved, worsened) was significant (p< 0.05). After effective treatment when clinical disease activity score improved by at least 2.5 points (n=18), the change of PROMIS score from Mobility, PB, PI, UE was significant (p< 0.05).

Conclusion: PROMIS pediatric measures  provide valuable information about  disease status of children with CNO and correlate well with functional and other psychosocial domains. Mobility, PI, and PB show sensitivity to change after effective treatment or with disease status change (better or worse). These instruments are useful for CNO clinical disease monitoring and research.

Supporting image 1

Table 1: Demographic characteristics

Supporting image 2

Table 2: PROMIS Pediatric Measures Correlated Well with Physician and Patient/Family Reported Outcomes

Supporting image 3

Figure 1: PROMIS Pediatric measures correlated with self-reported disease activity


Disclosures: M. Eckert: None; E. Wu: Pharming Healthcare, Inc, 1, 6, Sumitoma Pharma America, Inc, 1; M. Oliver: None; J. Scheck: None; S. Lapidus: None; U. Akca: None; S. Yasin: None; A. Lenert: None; S. Stern: None; A. insalaco: None; M. Pardeo: None; G. Simonini: None; E. Marrani: None; X. Wang: None; B. Huang: None; L. Kovalick: None; N. Rosenwasser: None; E. Balay-Dustrude: None; G. Casselman: None; L. Adriel: None; A. Klein: None; Y. Shao: None; C. Yang: None; M. Briggs: None; E. Deng: None; I. Hamilton: None; E. Mueller: None; E. Machrone: None; P. Trunnel: None; D. Mosa: None; L. Tucker: None; H. Girschick: None; R. Laxer: Akros pharma, 2, Eli Lilly canada, 2, Novartis, 2, Sanofi, 2, sobi, 2; G. Tiller: None; J. Akikusa: Pfizer, 1; C. Hedrich: Merck, 5; K. Onel: None; F. Dedeoglu: UpToDate, 9; M. Twilt: None; S. Ozen: Novartis, 2, 6, SOBI, 2, 6; P. Ferguson: None; L. Schanberg: Bristol-Myers Squibb(BMS), 5, Sanofi, 12, DSMB member, UCB, 12, DSMB Chair; B. Reeve: Novartis, 12, Guest speaker on advisory board, Observer-Reported Communication Ability (ORCA) measure, 12, part inventor for the Observer-Reported Communication Ability (ORCA) measure, receive licensing fees., Pro Pharma NH00006 US Meeting, 6; Y. Zhao: Bristol-Myers Squibb(BMS), 5.

To cite this abstract in AMA style:

Eckert M, Wu E, Oliver M, Scheck J, Lapidus S, Akca U, Yasin S, Lenert A, Stern S, insalaco A, Pardeo M, Simonini G, Marrani E, Wang X, Huang B, Kovalick L, Rosenwasser N, Balay-Dustrude E, Casselman G, Adriel L, Klein A, Shao Y, Yang C, Briggs M, Deng E, Hamilton I, Mueller E, Machrone E, Trunnel P, Mosa D, Tucker L, Girschick H, Laxer R, Tiller G, Akikusa J, Hedrich C, Onel K, Dedeoglu F, Twilt M, Ozen S, Ferguson P, Schanberg L, Reeve B, Zhao Y. Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/validation-of-patient-reported-outcomes-measurement-information-system-promis-pediatric-measures-for-children-with-chronic-nonbacterial-osteomyelitis-using-the-choir-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-patient-reported-outcomes-measurement-information-system-promis-pediatric-measures-for-children-with-chronic-nonbacterial-osteomyelitis-using-the-choir-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology